Research Article

The Efficacy and Safety of Traditional Chinese Medicine Tonifying-Shen (Kidney) Principle for Primary Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Junquan Liang,1 Fengyi Wang,2 Jiajia Huang,1 Yunxiang Xu,1, and Guizhen Chen2

1Clinical Medical School of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China
2The Bao’an District TCM Hospital, The Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Shenzhen 518101, Guangdong, China

Correspondence should be addressed to Yunxiang Xu; xuyx1968@163.com and Guizhen Chen; cgzhen2000@163.com

Received 8 April 2020; Revised 30 August 2020; Accepted 16 September 2020; Published 6 October 2020

Academic Editor: George B. Lenon

Copyright ©2020 Junquan Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study aimed to appraise the efficacy and safety of the tonifying-Shen (kidney) principle (TS (TK) principle) for primary osteoporosis (POP). Methods. Randomized controlled clinical trials (RCTs) using the TS (TK) principle for POP were searched from eight electronic databases to search for relevant literature that was published from the inception to September 2019. Two reviewers performed study selection, data extraction, data synthesis, and quality assessment independently. Review Manager 5.3 software was used to assess the risk of bias and conduct the data synthesis. We assessed the quality of evidence for outcomes by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Results. Thirty-six studies with 3617 participants were included. Meta-analysis showed a consistently superior effect of the TS (TK) principle combined with conventional Western medicine (CWM) in terms of total effectiveness rates (RR$=1.28; 95\% CI (1.23, 1.33); P<0.00001$), BMD of the lumbar spine (SMD$=0.71; 95\% CI (0.47, 0.95); P<0.00001$) and proximal femur (SMD$=0.94; 95\% CI (0.49, 1.38); P<0.00001$), TCM symptom integral (SMD$=−1.23; 95\% CI (−1.43, −1.02); P<0.00001$), and VAS scores (SMD$=−3.88; 95\% CI (−5.29, −2.46); P<0.00001$), when compared to using CWM alone and with significant differences. Besides, in respect of adverse effects, it showed no significant statistical difference between the experimental and control groups, RR$=1.00$ and 95\% CI (0.65, 1.51), $P=0.97$. Conclusion. Our meta-analysis provides promising evidence to suggest that using the TS (TK) principle combined with CWM for POP is more effective than using CWM alone. Also, both of them are safe and reliable for POP.

1. Introduction

Primary osteoporosis (POP), also called “a silent disease,” is one of the pandemic public health issues that seriously threaten people’s health all over the world [1]. Theoretically, POP and secondary osteoporosis belong to the field of osteoporosis (OP). POP includes two major types: postmenopausal osteoporosis (PMOP) and age-related or senile osteoporosis [2]. POP is characterized by decreased bone mass and degenerated bone microstructure, which contributes to a high risk of bone fragility and fracture [3, 4]. It is estimated that the number of individuals aged 50 years or over at high risk of osteoporotic fracture worldwide was at 158 million in 2010 and is set to double by 2040 [5]. In China, because of the largest population and the increasing proportion of elderly people, osteoporosis has become a severe challenge to the Chinese family, society, and government [6, 7]. Therefore, an effective prevention and treatment method is urgently needed for POP. Management of POP includes nonpharmacologic treatment and pharmacologic treatment. Conventional Western medicines (CWM) including antiresorptive or anabolic are widely used in the
treatment of POP [8–10]. However, due to adverse effects and risk of cancer, the use of CWM as long-term treatment is limited [11]. It is well documented that traditional Chinese medicine (TCM) is commonly combined with pharmacotherapy for POP in China [12–14]. In the theory of TCM, there is no particular disease named POP. According to the clinical symptoms, POP belongs to the TCM category of "Guwei (laxity of bones)," "Guku (dryness of bones)," "Guji (disease of bones)," "Gukong (depletion of bones), and Gubi (impediment of bones)" [15]. "Shen (kidney) dominating the bone" is the most fundamental theory in TCM. Shen essence (kidney essence) is closely related to bone physiology and pathology. The sufficient Shen essence can keep the bone healthy and strong. On the contrary, the deficiency of Shen essence will lead to a series of bone-related symptoms. Besides, "liver controlling tendon," is involved in bone health. Also, the spleen and stomach are considered as the postnatal foundations of organisms and are the material sources of bone growth. Therefore, the tonifying-Shen (kidney) principle (TS (TK) principle) mainly includes bushen huoxxe, bushen zhuanggu, bushen jianpi, and buyi ganshen, which are widely used in combination with other TCM therapies or CWM for the treatment of POP. And, this significant principle has its essential meaning in curing POP [16].

In recent years, numerous meta-analyses were carried out to investigate the efficacy of acupuncture or Chinese herbal medicine for POP [17]. However, there was still no sufficient evidence to draw definitive conclusions as most studies were not comparative analysis aiming at the effect of the TS (TK) principle for POP. Besides, most of the meta-analyses did not explore the safety of particular interventions. Therefore, the purpose of this study was to systematically identify available randomized clinical trials (RCTs) using the TS (TK) principle combined with CWM for POP to appraise its efficacy and safety.

2. Materials and Methods

2.1. Study Registration. The study has been registered in PROSPERO (registration number: CRD42020151768). The review reporting was conducted in compliance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement guidelines.

2.2. Study Design

2.2.1. Inclusion Criteria

(1) Types of Participants and Interventions. All RCTs that were reporting the application of the TS (TK) principle combined with CWM for POP were included. The interventions of these studies must include the TS (TK) principle in the experimental group. Studies must be published in English or Chinese language. TS (TK) principle mainly includes bushen huoxxe, bushen zhuanggu, bushen jianpi, and buyi ganshen. Specific treatment methods include traditional Chinese herbal medicine, acupuncture and moxibustion combined with traditional Chinese herbal medicine, acupoint catgut embedding, and acupoint injection. POP patients were included. There is no restriction on gender, race, ethnicity, or nation. Patients in the treatment group were given the TS (TK) principle combined with CWM, while patients in the control group were given CWM alone. The dosages and courses were not limited in our studies.

(2) Types of Outcome Measures. The primary outcomes included effectiveness rate and bone mineral density (BMD) of the lumbar spine and proximal femur (femoral neck or total hip). The secondary outcomes consisted of VAS scores and TCM symptom integral. Besides, adverse events were also assessed as a safety measurement.

2.2.2. Exclusion Criteria. Studies with the following characteristics were excluded: irrelevant to TS (TK) principle studies; studies without consistent diagnostic criteria or relevant outcome indicators; non-English or Chinese-language articles; duplicate reports or the data cannot be extracted; case reports, animal experiences, qualitative studies, comments, or review articles.

2.3. Literature Search Strategy. We searched four international electronic databases (PubMed, Cochrane Library, EMBASE, and Web of Science) and four Chinese electronic databases (CNKI, VIP, Wanfang, and CBM) from their initiation to September 2019 to collect for relevant literature. The literature search was constructed around search terms for TS (TK) principle, POP, and randomized controlled trials and adapted for each database as necessary. The references of the included studies were also screened for further material for inclusion. The detailed search strategy for PubMed is in Table 1. Search strategies were also used for other electronic databases.

2.4. Study Selection and Data Extraction. As a first step in the data handling process, titles and abstracts of all studies retrieved by the search strategies were screened for relevance, and all those that were clearly irrelevant have been discarded.

As a second step, two review team members (Junquan Liang and Fengyi Wang) independently assessed the eligibility of the studies by using the predefined inclusion and exclusion criteria. Besides, for the studies that meet the inclusion criteria, the whole article was read by reviewers to ensure that the entire study met the criteria and was prepared to extract relevant information. The disagreements on whether including a specific study or not were resolved by discussion between the reviewers. The lacking information was requested by contacting the writer of the original article.

The information extracted by the two independent review team members included the following: study setting, population study, participant demographics and baseline characteristics, details of the intervention and control conditions, study methodology, outcomes and treatment
Evidence-Based Complementary and Alternative Medicine

2.5. Risk of Bias Assessment. There were two reviewers involved in the quality assessment process, and any major disagreements were resolved by discussion to define the final set of included studies.

Two independent reviewers assessed the risk of bias by considering the following characteristics: randomization sequence generation, treatment allocation concealment, blinding method, completeness of outcome data, selective outcome reporting, and other sources of bias. Besides, the Cochrane Collaboration’s risk of bias assessment tool was used to assess the quality of the individual included studies.

2.6. Data Synthesis. Review Manager 5.3 software was used to carry out the quantitative synthesis. Mean difference (MD) or standardized mean difference (SMD) was used for continuous data. Risk ratio (RR) was used for the analysis of dichotomous data. Both were given a 95% confidence interval (CI). In the case of homogeneous data ($I^2 \leq 50\%$, $P > 0.10$), the fixed-effect model was adopted for the meta-analysis. Otherwise, the sources of heterogeneity were further analyzed. After excluding the influence of marked clinical heterogeneity, a random-effect model was adopted to perform the meta-analysis. Sensitivity and bias risk analyses were also performed.

2.6.1. Analysis of Subgroups. We performed some planned subgroup analysis: different specific therapies (bushen huoxue, bushen zhuanggu, bushen jianpi, and buyi ganshen) included in the TS (TK) principle, different kinds of treatment methods (traditional Chinese herbal medicine, acupuncture and moxibustion combined with traditional Chinese herbal medicine, acupoint catgut embedding, and acupoint injection), different parts of BMD examination (lumbar spine and proximal femur (femoral neck or total hip)), and different treatment periods of the TS (TK) principle ($\leq 3$ months, 3–6 months, and >6 months).

2.6.2. Sensitivity Analysis and Reporting Bias Analysis. Sensitivity analysis was carried out to identify the robustness and stability of pooled outcome results by removing the low-quality studies. We have performed a funnel plot of the primary outcome (effectiveness rates of different treatment methods included in the tonifying-Shen (kidney) principle) to evaluate the reporting bias.

2.7. Quality of Evidence. We assessed the quality of evidence for outcomes by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [18].

3. Results

3.1. Study Description and Participants. We obtained 390 relevant studies through preliminary searches. After multiple filtering steps, 36 RCTs with a total of 3617 participants were ultimately included in this systematic review. The flowchart of all study selection procedures is shown in Figure 1.

The 36 included studies involved 3617 participants. Among these studies, apart from combined with CWM, 23 studies reported using TCM herbal medicine [19–41], 5 studies reported using acupuncture and moxibustion combined with traditional Chinese herbal medicine [42–46], 9 studies reported using acupoint catgut embedding [25, 26, 40, 47–52], and 2 studies reported using acupoint injection [53, 54]. Besides, 3 studies divided their experimental group into two groups, respectively (acupoint catgut embedding group and TCM herbal medicine group) [25, 26, 40]. The detailed characteristics of the included studies are shown in Table 2.

3.2. Risk of Bias Assessment. We used the Cochrane Collaboration’s risk of bias assessment tool to assess the quality of the included studies. Firstly, all studies reported the method of randomization, and 30 studies described the method of generating a randomization number table [19–30, 32, 34, 35, 37–42, 44, 46, 48–54]. The remaining methods to achieve the sequence generation process include the following: drawing opaque envelope randomly [43], using Doll’s clinical case random table [47], drawing of lots, [36, 45], and tossing coins [31, 33]. Secondly, there were only 3 studies which achieved allocation concealment [19, 20, 43]. Thirdly, 3 studies were assessed as appropriate double-blinding of participants and provided detailed information for double-blinding during treatment as well as an outcome assessment [19, 20, 43]. None of the studies reported any incomplete outcome data (Table 3 and Figure 2).

3.3. Meta-Analysis

3.3.1. Effectiveness Rates of Different Treatment Methods Included in TS (TK) Principle. Twenty-five RCTs reported effectiveness rates of different treatment methods included in the TS (TK) principle [21–23, 25, 27, 28, 30, 31, 33, 34, 36–42, 44–50, 53]. Sixteen RCTs reported effectiveness rates of TCM herbal medicine [21–23, 25, 27, 28, 30, 31, 33, 34, 36–41], and there was low statistical heterogeneity among studies (chi$^2$ = 19.09, $P = 0.21$; $I^2 = 21\%$). Therefore, the fixed-effect model was applied to calculate the combined RR and 95% CI as 1.24 (1.19, 1.30), $P < 0.00001$, indicating a statistically significant difference between TCM herbal medicine combined with CWM and CWM alone. This result suggests that TCM herbal medicine combined with CWM in the treatment of POP can significantly improve clinical efficacy when compared with using CWM alone. Three studies reported effectiveness rates of acupuncture and moxibustion combined with TCM herbal medicine [42, 44, 45]. The result showed...
that there was no statistical heterogeneity among studies ($\chi^2 = 3.94, P = 0.14; I^2 = 49\%$), so we adopted a fixed-effect model to calculate the combined RR and 95% CI as 1.34 (1.19, 1.51), $P < 0.00001$, indicating a statistically significant difference between the experimental group and the control group. This result suggests that, in respect of effectiveness rates, using acupuncture and moxibustion combined with TCM herbal medicine plus CWM for POP was better than using CWM alone. There are 6 studies which reported effectiveness rates of acupoint catgut embedding [25, 40, 47–50]. The heterogeneity was not detected among studies ($\chi^2 = 4.53, P = 0.48; I^2 = 0\%$), so a fixed-effect model was used to calculate the combined RR and 95% CI as 1.42 (1.27, 1.58), $P < 0.00001$, indicating a statistically significant difference between acupoint catgut embedding combined with the CWM group and the CWM alone group. Owing to the small sample size, this result would show that the effectiveness rates of acupoint injection combined with CWM for POP were better than using CWM alone. All in all, the pooled data showed that different treatment methods included in the TS (TK) principle combined with CWM were more effective than using CWM alone in improving effectiveness rates, with significant differences (RR = 1.28; 95% CI (1.23, 1.33); $P < 0.00001$) (Figure 3(a)).

3.3.2. Effectiveness Rates of Different Specific Therapies Included in TCM Herbal Medicine. There were 16 studies which reported effectiveness rates of different specific therapies included in TCM herbal medicine [21–23, 25, 27, 28, 30, 31, 33, 34, 36–41]. Five studies reported the effectiveness rates of bushen huoexue therapy [23, 36–39], three studies reported the effectiveness rates of bushen zhuanggu therapy [27, 31, 33], three studies reported the effectiveness rates of bushen jianpi therapy [22, 28, 30], and five studies reported the effectiveness rates of buyi ganshen therapy [21, 25, 34, 40, 41]. The heterogeneity
among these studies was $\chi^2 = 3.07$, $P = 0.55$; $I^2 = 0\%$, $\chi^2 = 1.05$, $P = 0.59$; $I^2 = 0\%$, $\chi^2 = 1.16$, $P = 0.56$; $I^2 = 0\%$, and $\chi^2 = 3.02$, $P = 0.55$; $I^2 = 0\%$, respectively. Therefore, the fixed-effect model was applied to calculate the combined RR and 95% CI. After calculating, the combined RR and 95% CI was 1.18 (1.11, 1.24); $P < 0.00001$, 1.36 (1.21, 1.53); $P < 0.00001$, 1.34 (1.15, 1.57); $P = 0.0002$, and 1.21 (1.11, 1.32); $P < 0.00001$, respectively, indicating a statistically significant difference between the experimental group and the control group. This result suggests that bushen huoxue, bushen zhuanggu, bushen jianpi, and buyi ganshen TCM herbal medicine combined with CWM in the treatment of POP can significantly improve clinical efficacy when compared with using CWM alone. The combined data showed that different specific therapies included in TCM herbal medicine combined with CWM were more effective than using CWM alone in improving effectiveness rates, with significant differences (RR = 1.23; 95% CI (1.18, 1.29); $P < 0.00001$) (Figure 3(b)).

### 3.3.3. Effectiveness Rates of Different Treatment Periods

Twenty-three literature studies reported effectiveness rates of different treatment periods [21–23, 28–29, 30, 31, 33, 34, 37–42, 44, 45, 47–50, 53]. Eleven literature studies reported treatment periods of less than 3 months [23, 27, 28, 37, 38, 41, 44, 46, 48–50]. However, there was high statistical heterogeneity among studies ($\chi^2 = 22.88$, $P = 0.01$; $I^2 = 56\%$). A sensitivity analysis was performed to identify the source of heterogeneity. By removing one trial [38], no heterogeneity was detected ($\chi^2 = 4.88$, $P = 0.84$; $I^2 = 0\%$). We confirmed the accuracy of the data without publication bias after contacting the author. So, we adopted a random-effect model to calculate the combined RR and 95% CI as 1.35 (1.27, 1.43), $P < 0.00001$, indicating a statistically significant difference between the TS (TK) principle combined with the CWM group and the CWM alone group. It is suggested that using the TS (TK) principle combined with CWM for POP was better than using CWM alone in improving effectiveness rates when the treatment periods were less than 3 months. Twelve literature studies reported treatment periods of three to six months [21, 22, 25, 30, 31, 34, 39, 40, 42, 44, 47, 53]. There was no statistical heterogeneity among studies ($\chi^2 = 7.92$, $P = 0.85$; $I^2 = 0\%$). Therefore, the fixed-effect model was applied to calculate the combined RR and 95% CI as 1.25 (1.18, 1.32), $P < 0.00001$, indicating a statistically significant
difference between the TS (TK) principle combined with the CWM group and the CWM alone group. It is suggested that using the TS (TK) principle combined with CWM for POP was better than using CWM alone in improving effectiveness rates when the treatment periods were three to six months. The pooled data showed that different treatment periods combined with CWM were more effective than using CWM alone in improving effectiveness rates, with significant differences (RR = 1.29; 95% CI (1.24, 1.35); P < 0.00001) (Figure 3(c)).

3.3.4. BMD (Lumbar Spine) of Different Treatment Periods. Twenty-one studies reported BMD (lumbar spine) of different treatment periods [20, 21, 24, 25, 27, 29, 30, 32, 34, 35, 37–40, 42, 46, 48–50, 53, 54]. There were 8 studies which reported BMD (lumbar spine) of less than 3 months [27, 29, 37, 38, 48–50, 54], and 11 studies reported BMD (lumbar spine) of three to six months [21, 25, 30, 32, 34, 35, 39, 40, 42, 46, 53]. However, we detected high statistical heterogeneity among studies, chi² = 40.14, I² = 83% and chi² = 69.18, P < 0.00001; I² = 83%. The source of heterogeneity may be related to different treatment methods. Therefore, we adopted the random-effect model, and meta-analysis showed that there was a significant difference between the experimental and control groups (SMD = 0.83; 95% CI (0.52, 1.15); P < 0.00001 and SMD = 0.56; 95% CI (0.27, 0.85); P < 0.00001). It is suggested that using the TS (TK) principle combined with CWM less than three months or three to six months can both improve the BMD of the lumbar spine and is better than using CWM alone. Two studies reported BMD (lumbar spine) of more than six months [20, 24], and there was high statistical heterogeneity among studies (chi² = 49.53, P < 0.00001; I² = 98%). We adopted the random-effect model, and meta-analysis showed that there was no significant difference between the experimental and control groups (SMD = 1.36; 95% CI (1.33, 4.0); P = 0.32). In general, the meta-analysis showed that different treatment periods combined with CWM were more effective than using CWM alone in improving the BMD of the lumbar spine, with significant differences (SMD = 0.71; 95% CI (0.47, 0.95); P < 0.00001) (Figure 3(d)).

3.3.5. BMD (Proximal Femur (Femoral Neck or Total Hip)) of Different Treatment Periods. There were 15 studies which reported BMD (proximal femur (femoral neck or total hip)) of different treatment periods [19, 20, 24, 27, 30, 32, 34, 35, 37, 39, 42, 46, 51–53]. Two studies reported BMD (proximal femur (femoral neck or total hip)) of less than 3 months [27, 37]. High statistical heterogeneity among studies was detected (chi² = 10.41, P = 0.001; I² = 90%); therefore, we adopted the random-effect model, and meta-analysis showed that there was no significant difference between the experimental and control groups (SMD = 0.53; 95% CI (−0.30, 1.36); P = 0.21). Ten studies reported BMD (proximal femur (femoral neck or total hip)) of three to six months [30, 32, 34, 35, 39, 42, 46, 51–53]. There was high statistical heterogeneity among studies (chi² = 52.61, P < 0.00001; I² = 83%). We performed sensitivity analysis by removing one trial [35], and low heterogeneity was detected (chi² = 11.68, P = 0.17; I² = 32%). The source of heterogeneity may be related to different treatment methods. So, a random-effect model was adopted. The results showed that using the TS (TK) principle combined with CWM three to...
| No. | Included studies (author, year) | Control group | Age (years) | Participants (experimental group/control group) | Intervention | Experimental group | Outcomes | Secondary outcomes | Primary outcomes | Adverse effects (experimental group/control) | Treatment periods (months) | Follow-up (months) |
|-----|---------------------------------|---------------|-------------|-------------------------------------------------|--------------|------------------|----------|-------------------|----------------|----------------------|--------------------------|-------------------|
| 1   | Zhao et al. [9], 2019           |               | 63.9 ± 2.81 | 70/70                                           | Placebo capsules ± calcium carbonate | Buhen Yijing Fang ± calcium carbonate | —       | BMD of femoral neck | —              | 9/8                  | 36                       | 12                |
| 2   | Liu and Wang [12], 2016         |               | 56.15 ± 6.77| 62/62                                           | Alendronate sodium tablets ± calcium carbonate D3 tablets | Excil Buhen decoction ± acupuncture and moxibustion ± alendronate sodium tablets ± calcium carbonate D3 tablets | —       | Effectiveness rate | —              | 6                    | —                        | 6                 |
| 3   | Xu et al. [43], 2018            |               | 63.9 ± 1.79 | 32/31                                           | Calcium carbonate D3 | Thunder-fire moxibustion ± calcium carbonate D3 | VAS scores | —                | —              | —                    | 1                        | 1                 |
| 4   | Zhao et al. [20], 2012          |               | 64.9 ± 1.0  | 61/61                                           | Calcium carbonate ± vitamin D | Xian Ling Gu Bao capsules ± calcium carbonate ± vitamin D | VAS scores | —                | —              | 11/11                | 12                       | 12                |
| 5   | Zhao and Yan [21], 2018         |               | 61.3 ± 4.1  | 50/50                                           | Calcitrate ± alpha D3 ± calcichew D3 tablets | Traditional Chinese medicine prescription ± calcichew ± alpha D3 calcichew | VAS scores | —                | —              | 9/6                  | 6                        | 6                 |
| 6   | Liu et al. [22], 2014           |               | 65.5 ± 1.6  | 70/70                                           | Calcium carbonate D3 ± alendronate sodium tablets | Bushenhuoxuetang + calcium carbonate D3 ± alendronate sodium tablets | VAS scores | —                | —              | 2                    | —                        | 6                 |
| 7   | Wang et al. [23], 2018          |               | 65.1 ± 4.9  | 62.1 ± 1.4                                     | Calcitrate D400 | Calcium carbonate D3 | —       | BMD of femoral neck and lumbar spine | —              | 12                   | —                        | —                 |
| 8   | Xu et al. [24], 2018            |               | 63.7 ± 3.8  | 38/38                                           | Alendronate ± calcium carbonate D3 | Chinese herbal medicine ± alendronate ± calcium carbonate D3 | —       | Effectiveness rate | —              | 6                    | —                        | —                 |
| 9   | Liu et al. [25], 2011 (3)       | Liu 2011 (3)  | 60.8 ± 8.3  | A: 35/35 B: 35                                 | Calcichew D3 tablets | Liu 2011 (3) ± acupuncture catgut embedding ± calcichew D3 tablets | VAS scores | —                | —              | 6                    | —                        | —                 |
| 10  | Hu et al. [30], 2015            |               | 62.4 ± 6.3  | 60.8 ± 6.9                                     | Calcite D400 | Acupuncture catgut embedding ± calcium carbonate D3 | —       | Effectiveness rate | —              | 6                    | —                        | —                 |
| 11  | Liu et al. [31], 2011 (1)       | Liu 2011 (1)  | 67.4 ± 4.5  | 67.4 ± 3.8                                     | Calcichew D3 ± calcitriol soft capsules | Xian Ling Gu Bao capsules ± calcichew D3 ± calcitriol soft capsules | TCM symptom integral | —                | —              | 0/0/4                 | 6                        | 6                 |
| 12  | Peng et al. [32], 2018          |               | 62.8 ± 5.9  | A: 35/35 B: 35                                 | Calcichew D3 tablets ± alendronate sodium tablets | Calcichew D3 ± alendronate sodium tablets | VAS scores | —                | —              | 3                    | —                        | —                 |
| 13  | Peng et al. [33], 2018          |               | 65.4 ± 4.6  | 34/34                                           | Calcite D400 | Calcichew D3 ± alendronate sodium tablets | VAS scores | —                | —              | 3                    | 3                        | —                 |
| 14  | Li et al. [34], 2018            |               | 66.7 ± 3.71 | 60.6 ± 3.1                                     | Calcite D400 | Calcichew D3 ± alendronate sodium tablets | VAS scores | —                | —              | 3                    | 3                        | —                 |
| 15  | Ma et al. [35], 2018            |               | 68.43 ± 3.68| 42/42                                           | Calcium carbonate ± vitamin D tablets | Xian Ling Gu Bao capsules ± calcitriol soft capsules | VAS scores | —                | —              | 6                    | 6                        | 12                |
| 16  | Lin et al. [36], 2018           |               | 68.6 ± 5.7  | 24/22                                           | Osteoform capsules | Acupuncture catgut embedding ± osteoform capsules | —       | BMD of femoral neck | —              | 6                    | —                        | —                 |
| 17  | Lin et al. [37], 2016           |               | 67.4 ± 4.5  | 20/20                                           | Osteoform capsules | Acupuncture catgut embedding ± osteoform capsules | —       | BMD of femoral neck | —              | 6                    | —                        | —                 |
| 18  | Qi et al. [38], 2017            |               | 75.2 ± 2.83 | 100/100                                         | Calcite D | Bushenqiang fu ± calcite D | —       | BMD of femoral neck | —              | 3                    | 3                        | —                 |
| 19  | Liu et al. [39], 2017           |               | 73.4 ± 4.9  | 72.6 ± 5.5                                     | Calcitriol soft capsules ± calcite D | Busheojiaoyang fu ± calcite D | —       | BMD of femoral neck | —              | 3                    | —                        | —                 |
| 20  | Hu et al. [40], 2012            |               | 62.4 ± 1.5  | 155/155                                         | Calcite D | Shangyaoqian gao + calcite D + calcium carbonate D3 | —       | BMD of femoral neck | —              | 6                    | —                        | —                 |
| 21  | Ma et al. [41], 2018            |               | 59.8 ± 1.76 | 30/30                                           | Calcitriol soft capsules ± calcite D | Xian Ling Gu Bao capsules ± calcite D | VAS scores | —                | —              | 3                    | 3                        | —                 |
| 22  | Lin et al. [42], 2018           |               | 60.49 ± 7.23| 38/38                                           | Calcitriol soft capsules ± calcium carbonate D3 ± alendronate sodium tablets | —       | BMD of femoral neck | —              | 6                    | —                        | 6                 |
| 23  | Liu et al. [43], 2018           |               | 65.1 ± 4.9  | 60.49 ± 7.23                                   | Calcitriol soft capsules ± calcium carbonate D3 ± alendronate sodium tablets | —       | BMD of femoral neck | —              | 6                    | —                        | 6                 |
Table 2: Continued.

| No  | Included studies (author, year) | Age (years) | Participants (experimental group/control group) | Intervention | Outcomes | Secondary outcomes | Primary outcomes | Adverse effects (experimental group/control) | Treatment periods (months) | Follow-up (months) |
|-----|--------------------------------|-------------|-----------------------------------------------|--------------|----------|--------------------|-----------------|-----------------------------------------------|---------------------------|------------------|
| 24  | Chen et al. [31], 2017         | 66.2±11.3   | 32/28                                         | Salmon calcitonin Bushenjiangufang±salmon calcitonin | VAS scores  | Effectiveness rate  | —               | —                                             | 6                         | —                |
| 25  | Zou [32], 2016                | —           | 31/31                                         | Alendronate sodium tablets±calcichew D3 tablets Bushenjiangutang±alendronate sodium tablets±calcichew D3 tablets | —         | BMD of femoral neck and lumbar spine | Effectiveness rate; adverse effects | 0/0                        | 2               |
| 26  | Han [33], 2013               | 55.3±5.5    | 28/28                                         | Alfacalcidol soft capsules±calcichew D3 tablets Bushenjiangutang±alfacalcidol soft capsules±calcichew D3 tablets | —         | —                  | Effectiveness rate; BMD of femoral neck and lumbar spine | 6                         | 6                |
| 27  | Huang et al. [34], 2015       | 55.3±5.5    | 28/28                                         | Alfacalcidol soft capsules±calcichew D3 tablets Bushenjiangutang±alfacalcidol soft capsules±calcichew D3 tablets | —         | —                  | Effectiveness rate; adverse effects | 0/0                        | 6               |
| 28  | Huang et al. [35], 2017       | 55.3±5.5    | 28/28                                         | Alfacalcidol soft capsules±calcichew D3 tablets Bushenjiangutang±alfacalcidol soft capsules±calcichew D3 tablets | —         | —                  | Effectiveness rate; adverse effects | 0/0                        | 12              |
| 29  | Pan and Ding [37], 2014       | 57.2±11.2   | 56.9±11.0                                    | Oyster shell calcium capsules Bushenhuoxuefang±oyster shell calcium capsules | —         | —                  | Effectiveness rate; BMD of femoral neck and lumbar spine | 0/4                        | 3                |
| 30  | Wang [38], 2018               | 62.25±5.0   | 100/100                                       | Calcium carbonate and vitamin D3 tablets Bushenhuoxuefang±calcium carbonate and vitamin D3 tablets | —         | —                  | Effectiveness rate; BMD of lumbar spine | 3                         | —                |
| 31  | Gui et al. [39], 2017         | 66.28±5.17  | 66.19±5.34                                   | Alendronate sodium tablets±calcichew D3 tablets Bushenhuoxuefang±alendronate sodium tablets±calcichew D3 tablets | —         | —                  | Effectiveness rate; BMD of total hip and lumbar spine | 6                         | —                |
| 32  | Liu et al. [40], 2011 (2)     | 59.8±5.86   | 62.5±9.7, Liu 2011 (2)* 40.3±10.2             | Calcichew D3 tablets Liu 2011 (2)* 45/45 B 45 | —         | —                  | Effectiveness rate; BMD of lumbar spine | 4 Feb                     | 6                |
| 33  | OuYang et al. [41], 2016      | 60.6±5.6    | 64.4±5.3                                     | Alendronate Acupuncture and moxibustion±alendronate | —         | —                  | BMD of lumbar spine and proximal femur | —                         | 6                |
| 34  | Ouyang et al. [42], 2011      | 55.4±5.4    | 56.5±5.4                                     | Salmon calcitonin Acupoint injection | —         | —                  | BMD of lumbar spine | —                         | 2                |
| 35  | Zhou et al. [43], 2018        | 55.3±5.5    | 56.5±5.4                                     | Salmon calcitonin Acupoint injection | —         | —                  | BMD of lumbar spine | —                         | 2                |
| 36  | Xie et al. [44], 2018         | 61.0±3.12   | 59.4±4.12                                    | Vitamin D chewable tablets±calcitriol soft capsules Bushenfang±vitamin D chewable tablets±calcitriol soft capsules | —         | —                  | Effectiveness rate; adverse effects | 0/0                        | 3                |

Notes: the experimental group of Liu 2011 (1) was divided into 2 groups, respectively: Liu 2011 (1) and Liu 2011 (1)*; the experimental group of Liu 2011 (2) was divided into 2 groups, respectively: Liu 2011 (2) and Liu 2011 (2)*; the experimental group of Liu 2011 (3) was divided into 2 groups, respectively: Liu 2011 (3) and Liu 2011 (3)*. A: experimental group; B: control group.
| Study or subgroup | Experimental Events Total | Control Events Total | Weight (%) | Risk ratio M-H, fixed, 95% CI |
|------------------|--------------------------|---------------------|------------|-------------------------------|
| **1.1.1. TCM herbal medicine** |                          |                     |            |                              |
| Chen et al., 2017 | 31 32 22 28 2.6          | 28 2.6              | 1.23 [1.01, 1.51] |
| Gui et al., 2017 | 29 30 24 30 2.6          | 28 2.6              | 1.21 [1.00, 1.46] |
| Han, 2013        | 24 28 17 28 1.9          | 28 1.9              | 1.41 [1.01, 1.97] |
| Huang et al., 2018 | 67 88 61 88 6.7         | 88 6.7              | 1.10 [0.92, 1.32] |
| Huang, 2015      | 66 70 53 70 5.8          | 70 5.8              | 1.25 [1.08, 1.44] |
| Li et al., 2017  | 29 30 19 30 2.1          | 30 2.1              | 1.53 [1.15, 2.02] |
| Liu et al., 2011 (2) | 42 45 35 45 3.8        | 45 3.8              | 1.20 [1.01, 1.43] |
| Liu et al., 2011 (3) | 29 35 20 35 2.2        | 35 2.2              | 1.45 [1.05, 2.00] |
| Liu et al., 2018  | 34 38 27 38 3.0          | 38 3.0              | 1.26 [1.00, 1.59] |
| Pan et al., 2014 | 40 43 27 43 3.0          | 43 3.0              | 1.48 [1.16, 1.89] |
| Qi, 2016         | 92 100 66 100 7.2        | 100 7.2             | 1.39 [1.20, 1.62] |
| Song et al., 2015 | 85 90 75 90 8.2          | 90 8.2              | 1.13 [1.02, 1.26] |
| Wang, 2018       | 96 100 86 100 9.4        | 100 9.4             | 1.12 [1.02, 1.22] |
| Xie et al., 2018 | 42 45 32 45 3.5          | 45 3.5              | 1.31 [1.07, 1.61] |
| Yuan et al., 2014 | 31 40 24 40 2.6          | 40 2.6              | 1.29 [0.95, 1.75] |
| Zhao et al., 2018 | 47 49 39 48 4.3          | 48 4.3              | 1.18 [1.02, 1.37] |
| **Subtotal (95% CI)** | 863 858 69.1 | 69.1 | 1.24 [1.19, 1.30] |
| **Total events** | 784 627               |                     |            |                              |
| **Heterogeneity:** | $\chi^2 = 19.09$, df = 15 ($P = 0.21$); $I^2 = 21\%$ |
| **Test for overall effect:** | $Z = 9.40$ ($P < 0.00001$) |

| **1.1.2. Acupuncture and moxibustion combined with TCM herbal medicine** |                          |                     |            |                              |
| Han et al., 2011 | 29 30 20 30 2.2          | 30 2.2              | 1.45 [1.12, 1.88] |
| Liu et al., 2016 | 57 62 48 62 5.3          | 62 5.3              | 1.19 [1.02, 1.38] |
| Ma et al., 2018  | 40 42 26 42 2.9          | 42 2.9              | 1.54 [1.20, 1.97] |
| **Subtotal (95% CI)** | 134 134 10.3 | 10.3 | 1.34 [1.19, 1.51] |
| **Total events** | 126 94               |                     |            |                              |
| **Heterogeneity:** | $\chi^2 = 3.94$, df = 2 ($P = 0.14$); $P = 0.49$ |
| **Test for overall effect:** | $Z = 4.83$ ($P < 0.00001$) |

| **1.1.3. Acupoint catgut embedding** |                          |                     |            |                              |
| Liu et al., 2011(2)$^a$ | 43 45 35 45 3.8          | 45 3.8              | 1.23 [1.04, 1.45] |
| Liu et al., 2011(3)$^a$ | 32 35 20 35 2.2          | 35 2.2              | 1.60 [1.18, 2.17] |
| Lu, 2014         | 25 25 17 22 2.0          | 22 2.0              | 1.29 [1.02, 1.63] |
| Peng et al., 2017 | 29 35 20 35 2.2          | 35 2.2              | 1.45 [1.05, 2.00] |
| Peng et al., 2018 | 38 45 25 45 2.7          | 45 2.7              | 1.52 [1.14, 2.03] |
| Zhong et al., 2018 | 38 45 25 45 2.7          | 45 2.7              | 1.52 [1.14, 2.03] |
| **Subtotal (95% CI)** | 230 227 15.8 | 15.8 | 1.42 [1.27, 1.58] |
| **Total events** | 205 142             |                     |            |                              |
| **Heterogeneity:** | $\chi^2 = 4.53$, df = 5 ($P = 0.48$); $P = 0.00001$ |
| **Test for overall effect:** | $Z = 6.32$ ($P < 0.00001$) |

| **1.1.4. Acupoint injection** |                          |                     |            |                              |
| Zou et al., 2018 | 55 60 44 60 4.8          | 60 4.8              | 1.25 [1.05, 1.48] |
| **Subtotal (95% CI)** | 60 60 4.8 | 4.8 | 1.25 [1.05, 1.48] |
| **Total events** | 55 44             |                     |            |                              |
| **Heterogeneity:** | not applicable |
| **Test for overall effect:** | $Z = 2.56$ ($P < 0.01$) |
| **Total (95% CI)** | 1287 1279 100.0 | 100.0 | 1.28 [1.23, 1.33] |
| **Total events** | 1170 907            |                     |            |                              |
| **Heterogeneity:** | $\chi^2 = 12.54$, df = 25 ($P = 0.00001$); $P = 0.27\%$ |
| **Test for overall effect:** | $Z = 12.54$ ($P < 0.00001$) |

Test for subgroup differences: $\chi^2 = 5.75$, df = 3 ($P = 0.12$), $I^2 = 47.8\%$

(a)**

**Figure 3:** Continued.
| Study or subgroup | Experimental Events Total | Control Events Total | Weight (%) M-H, fixed, 95% CI | Risk ratio | Risk ratio M-H, fixed, 95% CI |
|------------------|--------------------------|----------------------|-------------------------------|------------|-----------------------------|
| Gui et al., 2017 | 29 30 24 30 3.7 1.21 [1.00, 1.46] | | | | |
| Huang, 2015      | 66 70 53 70 8.1 1.25 [1.08, 1.44] | | | | |
| Pan et al., 2014 | 66 70 53 70 8.1 1.25 [1.08, 1.44] | | | | |
| Song et al., 2015| 85 90 75 90 11.5 1.13 [1.02, 1.26] | | | | |
| Wang, 2018       | 96 100 86 100 13.1 1.12 [1.02, 1.22] | | | | |
| **Subtotal (95% CI)** | 360 | 360 | 44.4 | 1.18 [1.11, 1.24] | |
| Total events     | 342 | 291 | | | |
| Heterogeneity: chi² = 3.07, df = 4 (P = 0.55); I² = 0% | | | | | |
| Test for overall effect: Z = 5.70 (P < 0.00001) | | | | | |
| 1.2.2. Bushen zhuanggu | | | | | |
| Chen et al., 2017 | 31 32 22 28 3.6 1.23 [1.01, 1.51] | | | | |
| Qi, 2016         | 92 100 66 100 10.1 1.39 [1.20, 1.62] | | | | |
| **Subtotal (95% CI)** | 160 | 156 | 16.3 | 1.36 [1.21, 1.53] | |
| Total events     | 147 | 105 | | | |
| Heterogeneity: chi² = 1.05, df = 2 (P = 0.39); I² = 0% | | | | | |
| Test for overall effect: Z = 5.13 (P < 0.00001) | | | | | |
| 1.2.3. Bushen jianpi | | | | | |
| Li et al., 2017  | 29 30 19 30 2.9 1.53 [1.15, 2.02] | | | | |
| Liu et al., 2018 | 34 38 27 38 4.1 1.26 [1.00, 1.59] | | | | |
| **Subtotal (95% CI)** | 108 | 108 | 10.7 | 1.34 [1.15, 1.57] | |
| Total events     | 94 | 70 | | | |
| Heterogeneity: chi² = 1.16, df = 2 (P = 0.56); I² = 0% | | | | | |
| Test for overall effect: Z = 3.70 (P = 0.0002) | | | | | |
| 1.2.4. Buyi ganshen | | | | | |
| Huang et al., 2018 | 67 88 61 88 9.3 1.10 [1.02, 1.23] | | | | |
| Liu et al., 2011 (2) | 42 45 35 45 9.3 1.20 [1.01, 1.43] | | | | |
| Liu et al., 2011 (3) | 29 35 20 35 3.1 1.45 [1.05, 2.00] | | | | |
| Xie et al., 2018  | 42 45 32 45 4.9 1.31 [1.07, 1.61] | | | | |
| Zhao et al., 2018 | 47 49 39 48 6.0 1.18 [1.02, 1.37] | | | | |
| **Subtotal (95% CI)** | 262 | 261 | 28.6 | 1.21 [1.11, 1.32] | |
| Total events     | 227 | 187 | | | |
| Heterogeneity: chi² = 3.02, df = 4 (P = 0.55); I² = 0% | | | | | |
| Test for overall effect: Z = 4.18 (P < 0.00001) | | | | | |
| **Total (95% CI)** | 890 | 885 | 100.0 | 1.23 [1.18, 1.29] | |
| **Total events** | 810 | 653 | | | |
| Heterogeneity: chi² = 16.18, df = 15 (P = 0.057); I² = 7% | | | | | |
| Test for overall effect: Z = 9.36 (P < 0.00001) | | | | | |
| Test for subgroup differences: chi² = 6.54, df = 3 (P = 0.09), I² = 54.2% | | | | | |

(b) Figure 3: Continued.
### Experimental Study or subgroup Events

| Study or subgroup | Experimental Events | Control Events | Weight (%) | Risk ratio M-H, fixed, 95% CI |
|-------------------|---------------------|----------------|------------|-----------------------------|
| ≤3 months         |                     |                |            |                             |
| Han, 2013         | 24 28               | 17 28          | 2.0        | 1.41 [1.01, 1.97]           |
| Huang, 2015       | 66 70               | 53 70          | 6.3        | 1.25 [1.08, 1.44]           |
| Li et al., 2017   | 29 30               | 19 30          | 2.3        | 1.53 [1.15, 2.02]           |
| Ma et al., 2018   | 40 42               | 26 42          | 3.1        | 1.54 [1.20, 1.97]           |
| Pan et al., 2014  | 40 43               | 27 43          | 3.2        | 1.48 [1.16, 1.89]           |
| Peng et al., 2017 | 29 35               | 20 35          | 2.4        | 1.45 [1.05, 2.00]           |
| Peng et al., 2018 | 38 45               | 25 45          | 3.0        | 1.52 [1.14, 2.03]           |
| Qi, 2016          | 92 100              | 66 100         | 7.9        | 1.39 [1.20, 1.62]           |
| Wang, 2018        | 96 100              | 86 100         | 10.3       | 1.12 [1.02, 1.22]           |
| Xie et al., 2018  | 42 45               | 32 45          | 3.8        | 1.31 [1.07, 1.61]           |
| Zheng et al., 2018| 38 45               | 25 45          | 3.0        | 1.52 [1.14, 2.03]           |
| Total (95% CI)    | 583                 | 583            | 47.4       | 1.35 [1.27, 1.43]           |
| 3–6 months        |                     |                |            |                             |
| Chen et al., 2017 | 31 32               | 22 28          | 2.8        | 1.23 [1.01, 1.51]           |
| Gui et al., 2017  | 29 30               | 24 30          | 2.9        | 1.21 [1.00, 1.46]           |
| Han et al., 2011  | 29 30               | 20 30          | 2.4        | 1.45 [1.12, 1.88]           |
| Huang et al., 2018| 67 88               | 61 88          | 7.3        | 1.10 [0.92, 1.32]           |
| Liu et al., 2011 (2)* | 42 45             | 35 45          | 4.2        | 1.20 [1.01, 1.43]           |
| Liu et al., 2011 (2)' | 43 45             | 35 45          | 4.2        | 1.23 [1.04, 1.45]           |
| Liu et al., 2011 (3)* | 29 35             | 20 35          | 2.4        | 1.45 [1.05, 2.00]           |
| Liu et al., 2011 (3)' | 32 35             | 20 35          | 2.4        | 1.60 [1.18, 2.17]           |
| Liu et al., 2016  | 57 62               | 48 62          | 5.7        | 1.19 [1.02, 1.38]           |
| Liu et al., 2018  | 34 38               | 27 38          | 3.2        | 1.26 [1.00, 1.59]           |
| Lu, 2014          | 25 25               | 17 22          | 2.2        | 1.29 [1.02, 1.63]           |
| Yuan et al., 2014 | 31 40               | 24 40          | 2.9        | 1.29 [0.95, 1.75]           |
| Zhao et al., 2018 | 47 49               | 39 48          | 4.7        | 1.18 [1.02, 1.37]           |
| Zou et al., 2018  | 55 60               | 44 60          | 5.3        | 1.25 [1.05, 1.48]           |
| Total (95% CI)    | 614                 | 606            | 52.6       | 1.35 [1.18, 1.52]           |
| Total events      | 551                 | 436            |            |                             |

Heterogeneity: $\chi^2 = 7.92, df = 13 (P = 0.85); I^2 = 0$
Test for overall effect: $Z = 7.70 (P < 0.00001)$

| Total (95% CI) | 1197 | 1189 | 100.0 | 1.29 [1.24, 1.35] |
| Total events   | 1085 | 832  |       |                 |

Heterogeneity: $\chi^2 = 30.33, df = 24 (P = 0.17); I^2 = 21$
Test for overall effect: $Z = 12.32 (P < 0.000001)$
Test for subgroup differences: $\chi^2 = 3.57, df = 1 (P = 0.06), I^2 = 72.0$

(c) Figure 3: Continued.
| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Std. mean difference | IV, random, 95% CI | Std. mean difference | IV, random, 95% CI |
|------------------|------------------|----|-------|--------------|----|-------|--------|---------------------|-------------------|-------------------|-------------------|
| 1.4.1. ≤3 months |                  |    |       |              |    |       |        |                     |                   |                   |                   |
| Hu et al., 2012  | 0.743            | 0.058 | 155  | 0.703        | 0.051 | 145  | 4.8   | 0.73 (0.50, 0.96)   |                   |                   |                   |
| Pan et al., 2014 | 0.76             | 0.1  | 43    | 0.75         | 0.09  | 43   | 4.4   | 0.10 (-0.32, 0.53) |                   |                   |                   |
| Peng et al., 2017 | 0.74            | 0.015 | 35    | 0.674        | 0.117 | 35   | 4.2   | 0.78 (0.30, 1.27)  |                   |                   |                   |
| Peng et al., 2018 | 0.74            | 0.01  | 45    | 0.67         | 0.12  | 45   | 4.2   | 0.82 (0.38, 1.25)  |                   |                   |                   |
| Qi, 2016         | 0.85             | 0.07  | 100   | 0.77         | 0.02  | 100  | 4.7   | 1.55 (1.23, 1.86)  |                   |                   |                   |
| Wang, 2018       | 0.84             | 0.03  | 100   | 0.78         | 0.06  | 100  | 4.7   | 1.26 (0.96, 1.56)  |                   |                   |                   |
| Zhong et al., 2018 | 0.74         | 0.015 | 45    | 0.674        | 0.117 | 45   | 4.4   | 0.78 (0.36, 1.21)  |                   |                   |                   |
| Zhou et al., 2016 | 0.731           | 0.062 | 30    | 0.702        | 0.053 | 30   | 4.1   | 0.50 [-0.02, 1.01] |                   |                   |                   |
| Subtotal(95% CI) | 553             |     |       | 543          |     |      | 35.6  | 0.83 (0.52, 1.14)  |                   |                   |                   |
| Heterogeneity: tau^2 = 0.16, chi^2 = 40.14, df = 7 (P < 0.00001); I^2 = 83% |

Test for overall effect: Z = 5.22 (P < 0.00001)

| 1.4.2. 3–6 months |                  |    |       |              |    |       |        |                     |                   |                   |                   |
| Gui et al., 2017  | 0.83             | 0.1  | 30    | 0.74         | 0.09  | 30   | 4.1   | 0.93 (0.40, 1.47)  |                   |                   |                   |
| Huang et al., 2017 | 0.732           | 0.025 | 46    | 0.678        | 0.023 | 46   | 4.1   | 2.23 (1.70, 2.75)  |                   |                   |                   |
| Huang et al., 2018 | 0.817           | 0.122 | 88    | 0.788        | 0.146 | 88   | 4.7   | 0.21 [-0.08, 0.51] |                   |                   |                   |
| Liu et al., 2011(2) | 0.655         | 0.03  | 45    | 0.647        | 0.035 | 45   | 4.4   | 0.24 [-0.17, 0.66] |                   |                   |                   |
| Liu et al., 2011(2)* | 0.652        | 0.042 | 45    | 0.647        | 0.035 | 45   | 4.4   | 0.13 [-0.29, 0.54] |                   |                   |                   |
| Liu et al., 2011(3) | 0.669           | 0.047 | 35    | 0.648        | 0.032 | 35   | 4.2   | 0.52 (0.04, 0.99)  |                   |                   |                   |
| Liu et al., 2011(3)* | 0.672         | 0.035 | 35    | 0.649        | 0.032 | 35   | 4.2   | 0.68 (0.20, 1.16)  |                   |                   |                   |
| Liu et al., 2016  | 0.752           | 0.092 | 62    | 0.719        | 0.09  | 62   | 4.6   | 0.36 (0.01, 0.72)  |                   |                   |                   |
| Liu et al., 2018  | 0.94             | 0.14  | 38    | 0.87         | 0.13  | 38   | 4.3   | 0.51 (0.06, 0.97)  |                   |                   |                   |
| Ouyang et al., 2011 | 0.907          | 0.107 | 25    | 0.849        | 0.105 | 25   | 4.0   | 0.54 [-0.00, 1.08] |                   |                   |                   |
| Zhao et al., 2018  | 0.709           | 0.008 | 49    | 0.711        | 0.013 | 48   | 4.5   | -0.18 [-0.58, 0.21]|                   |                   |                   |
| Zou et al., 2018   | 0.85             | 0.05  | 60    | 0.8          | 0.06  | 60   | 4.5   | 0.90 (0.52, 1.28)  |                   |                   |                   |
| Zou, 2016          | 0.75             | 0.15  | 31    | 0.69         | 0.12  | 31   | 4.2   | 0.44 [-0.07, 0.94] |                   |                   |                   |
| Subtotal(95% CI)   | 589             |     |       | 593          |     |      | 56.2  | 0.56 (0.27, 0.85)  |                   |                   |                   |
| Heterogeneity: tau^2 = 0.23, chi^2 = 69.18, df = 12 (P < 0.00001); I^2 = 83% |

Test for overall effect: Z = 3.84 (P = 0.00001)

| 1.4.3. >6 months |                  |    |       |              |    |       |        |                     |                   |                   |                   |
| Wu et al., 2005   | 0.821            | 0.12  | 34    | 0.518        | 0.097 | 34   | 3.6   | 2.75 (2.07, 3.42)  |                   |                   |                   |
| Zha et al., 2012   | 0.77            | 0.1   | 56    | 0.77         | 0.1   | 60   | 4.5   | 0.00 [-0.36, 0.36] |                   |                   |                   |
| Subtotal(95% CI)   | 90              |     |       | 94           |     |      | 8.2   | 1.36 [-1.33, 4.05] |                   |                   |                   |
| Heterogeneity: tau^2 = 3.69, chi^2 = 9.53, df = 1 (P < 0.00001); I^2 = 98% |

Test for overall effect: Z = 0.99 (P = 0.32)

| Total (95% CI)    | 1232            |     |       | 1230         |     |      | 100.0 | 0.71 (0.47, 0.95)  |                   |                   |                   |
| Heterogeneity: tau^2 = 0.30, chi^2 = 180.53, df = 22 (P < 0.00001); I^2 = 88% |

Test for overall effect: Z = 5.76 (P < 0.00001)

---

**Figure 3**: Continued.
### Study or subgroup

| Experimental | Control | Weight (%) | Std. mean difference | Std. mean difference |
|--------------|---------|------------|----------------------|----------------------|
| Mean | SD | Total | Mean | SD | Total |

#### 1.5.1. ≤3 months

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|------------------|----|-------|-------------|----|-------|------------|----------------------|----------------------|
| Pan et al., 2014 | 0.09 | 0.33 | 43 | 0.51 | 43 | 6.8 | 0.71 | 0.12 | 0.7 | 0.143 | 43 | 6.8 |
| Qi, 2016 | 0.94 | 1.23 | 0.8 | 0.06 | 0.08 | 7.0 | 0.75 | 0.08 | 7.0 | 0.71 | 0.143 | 143 | 13.8 |
| Subtotal (95% CI) | 0.53 | (0.30, 1.36) |

Heterogeneity: $\tau^2 = 0.32$, chi$^2 = 10.41$, df = 1 ($P = 0.001$); $I^2 = 90$

Test for overall effect: $Z = 1.25 (P = 0.21)$

#### 1.5.2. 3–6 months

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|------------------|----|-------|-------------|----|-------|------------|----------------------|----------------------|
| Gui et al., 2017 | 0.94 | 1.23 | 0.8 | 0.06 | 0.08 | 7.0 | 0.75 | 0.08 | 7.0 | 0.71 | 0.143 | 143 | 13.8 |
| Huang et al., 2017 | 0.53 | (0.30, 1.36) |

Heterogeneity: $\tau^2 = 0.25$, chi$^2 = 52.61$, df = 9 ($P < 0.00001$); $I^2 = 83$

Test for overall effect: $Z = 3.89 (P = 0.001)$

#### 1.5.3. >6 months

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|------------------|----|-------|-------------|----|-------|------------|----------------------|----------------------|
| Wu et al., 2017 | 0.81 | 0.13 | 30 | 0.09 | 0.09 | 30 | 6.5 | 0.71 | 0.09 | 6.8 | 0.143 | 43 | 6.8 |
| Zheng et al., 2019 | 0.69 | (2.40, 3.84) |
| Zhou et al., 2012 | 0.74 | (2.70, 3.71) |
| Subtotal (95% CI) | 0.32 | (0.30, 1.36) |

Heterogeneity: $\tau^2 = 0.73$, chi$^2 = 222.50$, df = 14 ($P < 0.00001$); $I^2 = 94$

Test for overall effect: $Z = 11.63 (P < 0.00001)$

### Study or subgroup

| Experimental Events | Control Events | Weight (%) | Risk ratio | Risk ratio |
|---------------------|---------------|------------|------------|------------|
| Mean | SD | Total | Mean | SD | Total |

#### 1.5.1. ≤3 months

| Study or subgroup | Experimental Events | Control Events | Weight (%) | Risk ratio | Risk ratio |
|------------------|---------------------|---------------|------------|------------|------------|
| Gui et al., 2017 | 2 | 30 | 10.6 | 0.50 | (0.10, 2.53) |
| Han, 2013 | 0 | 28 | Not estimable |
| Huang et al., 2018 | 0 | 28 | Not estimable |
| Liu et al., 2018 | 6 | 38 | 10.6 | 1.50 | (0.46, 4.89) |
| Pan et al., 2014 | 0 | 43 | 12.0 | 0.11 | (0.01, 2.00) |
| Song et al., 2015 | 0 | 90 | Not estimable |
| Xie et al., 2018 | 0 | 30 | Not estimable |
| Zhao et al., 2018 | 9 | 49 | 16.1 | 1.47 | (0.57, 3.81) |
| Zheng et al., 2019 | 9 | 57 | 21.4 | 1.11 | (0.46, 2.66) |
| Zhu et al., 2012 | 11 | 56 | 29.2 | 1.00 | (0.47, 2.12) |
| Zou et al., 2018 | 0 | 60 | Not estimable |
| Total (95% CI) | 569 | 567 | 100.0 | 0.99 | (0.65, 1.51) |
| Total events | 37 | 37 | |

Heterogeneity: $\chi^2 = 4.07$, df = 5 ($P = 0.54$); $I^2 = 0$

Test for overall effect: $Z = 0.04 (P = 0.97)$

### Study or subgroup

| Experimental Mean | Control Mean | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|-------------|------------|----------------------|----------------------|
| Mean | SD | Total | Mean | SD | Total |

#### 1.5.2. 3–6 months

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|------------------|----|-------|-------------|----|-------|------------|----------------------|----------------------|
| Liu et al., 2011(1) | 3.06 | 1.86 | 35 | 5.37 | 22.6 | 35 | 16.8 | 0.57 | 0.12 | 0.57 | 0.143 | 143 | 13.8 |
| Liu et al., 2011(1) | 3.26 | (0.57, 3.81) |
| Liu et al., 2011(2) | 3.24 | (1.97, 3.71) |
| Liu et al., 2011(3) | 3.23 | (1.97, 3.71) |
| Liu et al., 2011(4) | 3.22 | (1.97, 3.71) |
| Ouyang et al., 2011 | 3.9 | 31 | 25 | 7.1 | 2.9 | 30 | 13.2 | 0.71 | 0.09 | 6.8 | 0.143 | 43 | 6.8 |
| Zou et al., 2016 | 5.2 | 0.6 | 30 | 6.1 | 0.4 | 30 | 11.9 | 0.71 | 0.09 | 6.8 | 0.143 | 43 | 6.8 |
| Subtotal (95% CI) | 215 | 220 | 100.0 | 1.23 | (1.43, 1.02) |

Heterogeneity: $\chi^2 = 7.49$, df = 5 ($P = 0.19$); $I^2 = 33$

Test for overall effect: $Z = 11.63 (P = 0.00001)$

---

Figure 3: Continued.
six months can improve the BMD of the proximal femur (femoral neck or total hip) and was better than using CWM alone (SMD \( \approx 0.69; 95\% \text{ CI} (0.34, 1.04); P < 0.00001 \)). Three studies reported BMD of more than six months, and these showed that there was high heterogeneity (chi\(^2\) = 135.92, \( P < 0.00001 \); \( I^2 = 99\% \)) [19, 20, 24]. By removing one study [20], no heterogeneity was detected. The high heterogeneity may result from different treatment methods adopted by these studies. Thus, a random-effect model was adopted, and the results showed that there was no significant difference between the experimental and control groups (SMD = 2.06; 95% CI (0.36, 4.49); \( P = 0.10 \)). The combined data showed that different treatment periods combined with CWM were more effective than using CWM alone in improving the BMD of the proximal femur (femoral neck or total hip), with significant differences (SMD = 0.94; 95% CI (0.49, 1.38); \( P < 0.00001 \)) (Figure 3(e)).

3.3.6. Adverse Effects. Eleven studies reported adverse effects [19–21, 30, 33, 34, 36, 37, 39, 41, 53], and there was no statistical heterogeneity among studies (chi\(^2\) = 4.07, \( P = 0.54; I^2 = 0\% \)). Hence, the fixed-effect model was applied to calculate the combined RR and 95% CI as 0.99 (0.65, 1.51), \( P = 0.97 \), indicating no statistically significant difference between the experimental group and the control group. This result suggests that the TS (TK) principle combined with CWM or using CWM alone in the treatment of POP are both safe. Besides, the common adverse effects in the experimental group were gastrointestinal complaints, liver enzyme

### Table 1: BMD at Different Treatment Periods

| Study or subgroup | Experimental | Control | Weight (%) | Std. mean difference | Std. mean difference |
|------------------|--------------|---------|------------|----------------------|----------------------|
| Mean SD Total | Mean SD Total | IV random, 95% CI | IV random, 95% CI |
| Chen et al., 2017 | 2.14 0.03 70 | 2.14 0.16 70 | 1.5 | 1.91 [1.41, 2.41] |
| Huang, 2015 | 1.15 0.03 70 | 2.14 0.16 70 | 4.3 | 8.55 [-9.62, 7.48] |
| Liu et al., 2011(2) | 3.34 0.71 45 | 2.02 0.66 45 | 2.0 | 1.86 [-1.01, -0.25] |
| Liu et al., 2011(2)* | 1.53 0.78 45 | 2.02 0.66 45 | 1.5 | 1.86 [-1.01, -0.25] |
| Liu et al., 2011(3) | 2.03 0.67 35 | 3.31 0.73 35 | 1.5 | 2.31 [-2.92, -1.69] |
| Liu et al., 2011(3)* | 1.5 0.82 35 | 3.31 0.73 35 | 1.5 | 2.31 [-2.92, -1.69] |
| Peng et al., 2017 | 2.23 0.16 35 | 4.16 0.20 35 | 2.4 | 10.36 [-12.19, -8.53] |
| Peng et al., 2018 | 2.24 0.16 45 | 4.17 0.2 45 | 7.8 | 10.57 [-12.20, -8.93] |
| Xu et al., 2018 | 2.77 0.92 32 | 4.18 0.28 31 | 2.0 | 1.09 [-1.62, -0.56] |
| Zhao et al., 2018 | 1.4 0.5 49 | 1.9 0.4 48 | 2.0 | 1.09 [-1.52, -0.67] |
| Zhong et al., 2018 | 2.23 0.16 45 | 4.16 0.20 45 | 7.8 | 10.39 [-12.00, -8.78] |

Total (95% CI) 556 550 100.0 –3.88 [–5.29, –2.46]

Test for overall effect: \( Z = 5.37 \) (\( P < 0.00001 \))
abnormal, hypertension, joint pain, stomach discomfort, nausea, vomiting, headache, musculoskeletal pain, etc. The adverse effects in the control group included gastrointestinal complaints, liver enzyme abnormal, hypertension, nausea, and vomiting (Figure 3(f)).

3.3.7. TCM Symptom Integral. The TCM symptom integral was established according to the Clinical Research Guidance of New Chinese Herbal Medicine [55]. Four studies reported TCM symptom integral [26, 40, 46, 54], and there was low statistical heterogeneity among studies ($\chi^2 = 7.49$, p = 0.05).

| Quality assessment | No. of patients | Effect |
|--------------------|-----------------|--------|
|                     | No. of studies  | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TS (TK) principle combined with CWM | CWM | Relative (95% CI) | Absolute | Quality | Importance |
| Effectiveness rates of different treatment methods included in TS (TK) principle (follow-up 0-6 months) | 25 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | dose response gradient³ | 1170/1287 (90.9%) | 907/1279 (70.9%) | RR 1.28 (1.23 to 1.33) | 199 more per 1000 (from 163 more to 234 more) | CRITICAL MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    |                 |    |                         |
|                                                                             |                |        |              |              |               |              |                        |                    | 70.2%                               |
| Effectiveness rates of different specific therapies included in TCM herbal medicine (follow-up 0-6 months) | 16 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | dose response gradient³ | 810/890 (91%) | 653/885 (73.8%) | RR 1.23 (1.18 to 1.29) | 170 more per 1000 (from 133 more to 214 more) | CRITICAL MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    | 73.4%                               |
|                                                                             |                |        |              |              |               |              |                        |                    | 169 more per 1000 (from 132 more to 213 more) |
| Effectiveness rates of different treatment periods (follow-up 0-6 months) | 23 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | dose response gradient³ | 1085/1197 (90.6%) | 932/1189 (79%) | RR 1.29 (1.24 to 1.35) | 203 more per 1000 (from 168 more to 245 more) | CRITICAL MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    | 69.3%                               |
|                                                                             |                |        |              |              |               |              |                        |                    | 201 more per 1000 (from 166 more to 243 more) |
| BMD (lumbar spine) of different treatment periods (follow-up 0-12 months; better indicated by lower values) | 21 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | no strong association⁴ | 1232 | 1230 | — | SMD 0.71 higher (0.47 to 0.95 higher) | CRITICAL MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    |                                      |
| BMD (proximal femur (femoral neck or total hip)) of different treatment periods (follow-up 0-12 months; better indicated by lower values) | 15 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | no strong association⁴ | 727 | 732 | — | SMD 0.84 higher (0.49 to 1.38 higher) | CRITICAL MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    |                                      |
| Adverse effects (follow up 0-12 months) | 11 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | no strong association⁴ | 37/567 (6.5%) | 37/569 (6.5%) | RR 0.99 (0.85 to 1.15) | 1 fewer per 1000 (from 21 fewer to 33 more) | LOW |
|                                                                             |                |        |              |              |               |              |                        |                    | 9.3%                                |
|                                                                             |                |        |              |              |               |              |                        |                    | 1 fewer per 1000 (from 35 fewer to 47 more) |
| TCM symptom integral (better indicated by lower values) | 4 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | no strong association⁴ | 215 | 220 | — | SMD 1.23 lower (1.43 to 1.02 lower) | IMPORTANT MODERATE |
|                                                                             |                |        |              |              |               |              |                        |                    |                                      |
| VAS scores (follow up 0-6 months; better indicated by lower values) | 10 | randomised trials | serious¹ | no serious inconsistency | serious² | no serious imprecision | no strong association⁴ | 556 | 550 | — | SMD 3.88 lower (5.29 to 2.46 lower) | IMPORTANT MODERATE |

1: Most of the literature can't be double blinded
2: Surrogates measures
3: Increasing the intensity of intervention would increase the efficacy
4: SMD > 0.70 represents a large effect

**Figure 5: GRADE evidence profile.**
| No. | Included studies (first author, year) | Random sequence generation | Allocation concealment | Blinding of participants, personnel, and outcome assessors | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
|-----|-------------------------------------|-----------------------------|-----------------------|-----------------------------------------------------------|------------------------|-----------------------------|----------------------|
| 1   | Zheng et al. [19], 2019             | Randomization number table  | Yes                   | Yes                                                       | Yes                    | No                          | No                   |
| 2   | Liu and Wang [42], 2016             | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 3   | Xu et al. [43], 2018                | Draw opaque envelope randomly| Yes                   | Yes                                                       | Yes                    | No                          | No                   |
| 4   | Zhu et al. [20], 2012               | Using a computer random number generator | Yes | Yes | Yes | No | No |
| 5   | Zhao et al. [21], 2018              | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 6   | Yuan et al. [22], 2014              | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 7   | Huang [23], 2015                    | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 8   | Wu et al. [24], 2005                | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 9   | Liu et al. [25], 2011 (3)           | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 10  | Lu [47], 2014                       | Doll’s clinical case random table | Unclear | Unclear | Yes | No | No |
| 11  | Han et al. [44], 2011               | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 12  | Liu et al. [26], 2011 (1)           | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 13  | Peng et al. [48], 2017              | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 14  | Peng et al. [49], 2018              | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 15  | Zhong et al. [50], 2018             | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 16  | Zou et al. [53], 2018               | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 17  | Ma et al. [45], 2018                | Drawing of lots             | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 18  | Lin [51], 2006 (1)                  | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 19  | Lin [52], 2006 (2)                  | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 20  | Qi [27], 2016                       | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 21  | Li et al. [28], 2017                | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 22  | Hu and Li [29], 2012                | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 23  | Liu and Gong [30], 2018             | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 24  | Chen et al. [31], 2017              | Coin tossing                | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 25  | Zou [32], 2016                      | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 26  | Han [33], 2013                      | Coin tossing                | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 27  | Huang et al. [34], 2018             | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No                   |
| 28  | Huang et al. [35], 2017             | Randomization number table  | Unclear               | Unclear                                                   | Yes                    | No                          | No |
$P = 0.19; I^2 = 33\%$). Therefore, the fixed-effect model was applied. The meta-analysis showed that there was a statistically significant difference between the experimental group and the control group (SMD = −1.23; 95% CI (−1.43, −1.02); $P < 0.00001$). This result suggests that the TS (TK) principle combined with CWM in the treatment of POP can significantly improve TCM symptom integral when compared with using CWM alone (Figure 3(g)).

3.3.8. VAS Scores. There were 10 studies which reported VAS scores [21, 23, 25, 31, 34, 40, 43, 48–50]. The result showed that there was high statistical heterogeneity among studies ($\chi^2 = 733.80, P < 0.00001; I^2 = 99\%$), so we adopted a random-effect model. The combined data showed that there was a statistically significant difference between the experimental group and the control group (SMD = −3.88; 95% CI (−5.29, −2.46); $P < 0.00001$). This result suggests that the TS (TK) principle combined with CWM in the treatment of POP was more effective than using CWM alone in improving VAS scores (Figure 3(h)).

3.3.9. Publication Bias. The funnel plots were generated for studies with data on the effectiveness rates of different treatment methods included in the TS (TK) principle. The results showed that most of the points in the funnel plots were symmetrical. However, two points were outside the 95% CIs, which indicates that there may have been publication bias in our studies and that might influence the results of our analysis, as can be seen in Figure 4.

3.3.10. Quality of Evidence. There were 8 results for levels of evidence in our study. The detailed GRADE evidence profile of results is shown in Figure 5.

### Table 3: Continued.

| No. | Included studies (first author, year) | Random sequence generation | Allocation concealment | Blinding of participants, personnel, and outcome assessors | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
|-----|-------------------------------------|---------------------------|-----------------------|----------------------------------------------------------|-------------------------|---------------------------|---------------------|
| 29  | Song et al. [36], 2015              | Draw lots randomly        | Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 30  | Pan and Ding [37], 2014            | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 31  | Wang [38], 2018                    | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 32  | Gui et al. [39], 2017              | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 33  | Liu et al. [40], 2011 (2)          | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 34  | Ouyang et al. [46], 2011           | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 35  | Zhou et al. [54], 2016             | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |
| 36  | Xie et al. [41], 2018              | Randomization number table| Unclear               | Unclear                                                  | Yes                     | No                        | No                  |

4. Discussion

4.1. Summary of Main Results. There were 36 included RCTs with 3617 participants in our research. Even though most of the trials had small sample sizes and poor methodological quality, our meta-analysis reached the following results: (1) analysis of the pooled data showed a consistently superior effect of the TS (TK) principle combined with CWM in terms of total effectiveness rates, BMD of the lumbar spine and proximal femur (femoral neck or total hip), TCM symptom integral, and VAS scores when compared to using CWM alone; (2) in terms of adverse effects, the same safety was obtained for the TS (TK) principle combined with CWM or using CWM alone for POP; (3) different treatment methods included in the TS (TK) principle combined with CWM were more effective than using CWM alone in improving effectiveness rates. It should be noted that since the sample size of acupoint injection effectiveness rates was small, the combined RR and 95% CI was reported from the original study, not from the meta-analysis results; (4) in respect of TCM herbal medicine, different specific therapies combined with CWM for POP were more effective than using CWM alone; (5) compared with using CWM alone, the TS (TK) principle combined with CWM was more effective for POP in the aspect of different treatment periods; (6) in the three-to six-month treatment period, the TS (TK) principle combined with CWM for POP in terms of BMD of the lumbar spine and proximal femur (femoral neck or total hip) was better than using CWM alone; (7) according to the guideline of GRADE, the effectiveness rates of different treatment methods included in the TS (TK) principle, effectiveness rates of different specific therapies included in TCM herbal medicine, effectiveness rates of different treatment periods, BMD (lumbar spine) of different treatment periods, BMD (proximal femur (femoral neck or total hip)) of different treatment periods, TCM
symptom integral, and VAS scores were moderate level of evidence. The adverse effects were low of evidence.

4.2. Analysis of TS (TK) Principle. TCM has been used in a range of medical management and health interventions in China and any other Asian countries for over 2500 years. POP patients are usually seeking TCM treatment, when the therapeutic effect of CWM is unsatisfactory. According to TCM theory, the establishment of a therapeutic principle is based on TCM syndromes, not symptoms. The clinical diagnosis of the TCM syndrome relies on the gathering of clinical information through inspection, auscultation and olfaction, inquiry, and palpation [56]. For POP, the fundamental physiopathological changes of the bone depend on whether Shen (kidney) essence is sufficient or not. Therefore, the TS (TK) principle is the key point to prevent and treat Shen (kidney)-deficiency syndrome of POP [57–60]. On the one hand, the effective mechanisms of pharmaceutical treatment included in the TS (TK) principle on POP have been demonstrated in the voluminous literature. Icariin (ICA), similar to estrogen, has a definite antiosteoporotic effect [61, 62]. Besides, oleanolic acid (OA) and psoralen have been reported to prevent bone loss by inhibiting osteoclast formation [63–65]. On the other hand, in respect of nonpharmaceutical treatment included in the TS (TK) principle, experiments have demonstrated that acupuncture could alleviate osteoporosis by regulating the expression of members in OPG/RANKL, Wnt/β-catenin, and MAPK pathways [66]. Acupoint catgut embedding could regulate the hypothalamic-pituitary-ovarian axis to raise the serum E_2 level which would be significant in preventing osteoporosis [67]. Even experiments have shown that acupoint catgut embedding ameliorated the ovariectomization- (OVX-) caused metabonomic changes more effectively than hormone replacement therapy (HRT) with nilestriol [68]. Also, nonpharmaceutical treatment could alleviate related symptoms of osteoporosis and improve the quality of life [43]. Therefore, the TS (TK) principle would be a promising approach for POP, and it can not only improve physiological and biochemical indicators but also alleviate the TCM syndromes [16].

4.3. Limitations of Research. However, some limitations in our meta-analysis should be mentioned. (1) Although all of our included studies were RCTs, the methodological quality of them was generally improvable. Most of them failed to describe the blinding methods in detail, allocation, and concealment methods. (2) Among 36 studies, only 8 studies reported follow-up. The longest follow-up period was 120 months, and no further follow-up data were collected. The long-term effect of the TS (TK) principle for POP should be further studied. (3) For POP, fracture incidence should be the most patient-important outcomes. However, no fracture incidence data were collected in our studies. It is necessary to focus on fracture incidence as a patient-important outcome in further studies. (4) The studies included in this analysis were insufficient, especially in terms of subgroup analysis. Thus, potential publication bias probably exists. (5) The high heterogeneity among studies may be related to the different treatment methods, treatment periods, and even the skill level of the practitioners. It is a common problem in the research of TCM therapy. (6) The study for different specific therapies of TCM herbal medicine was insufficient, and further data mining should be carried out.

5. Conclusion

In summary, our meta-analysis suggests that using the TS (TK) principle combined with CWM for POP is effective and safe. However, the limitation in the quality and quantity of the included RCTs might weaken the overall reliability of this conclusion. Therefore, large-volume, well-designed RCTs with extensive follow-up are awaited to confirm and update the findings of this analysis.

Abbreviations

POP: Primary osteoporosis
OP: Osteoporosis
PMOP: Postmenopausal osteoporosis
CWM: Conventional Western medicines
TCM: Traditional Chinese Medicine
TS (TK): Tonifying-Shen (kidney) principle
RCTs: Randomized clinical controlled trials
BMD: Bone mineral density
VAS: Visual analogue scale
PRISMA: Preferred reporting item for systematic review and meta-analysis
CNKI: China National Knowledge Infrastructure
VIP: Chinese Scientific Journal Database
CBM: China Biology Medicine
MD: Mean difference
SMD: Standardized mean difference
RR: Risk ratio
95% CI: 95% confidence interval
GRADE: Grading of Recommendations Assessment, Development, and Evaluation
ICA: Icariin
OA: Oleanolic acid
OVX: Ovariectomization
HRT: Hormone replacement therapy

Data Availability

The data used to support the findings of this study have been deposited in the following repository: PubMed: https://www.ncbi.nlm.nih.gov/pubmed/; Cochrane Library: https://www.cochranelibrary.com/; EMBASE: https://www.embase.com/; Web of Science: http://webofscience.com/; CNKI: https://www.cnki.net/; VIP: http://www.cqvip.com/; Wanfang: http://www.wanfangdata.com.cn/; CBM: http://www.sinomed.ac.cn/.

Conflicts of Interest

The authors have no conflicts of interest to disclose.
Authors’ Contributions
Junquan Liang, Guizhen Chen, and Yunxiang Xu conceptualized the study and were responsible for writing–review and editing. Yunxiang Xu and Junquan Liang curated the data. Junquan Liang and Fengyi Wang performed formal analysis and were responsible for methodology, resources, software, visualization, and writing–original draft. Guizhen Chen and Yunxiang Xu were responsible for project administration.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (grant no. 81574064, Yunxiang Xu; 81473755, Guizhen Chen); the Shenzhen Science and Technology Planning Project (grant no. JCYJ20170306152650625); the Shenzhen Bao’an District TCM Hospital Research Program (no. BAYZY20200609).

References
[1] C. D. Wylie, “Setting a standard for a “silent” disease: defining osteoporosis in the 1980s and 1990s,” Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, vol. 41, no. 4, pp. 376–385, 2010.
[2] H. Orimo, Y. Sugiyori, M. Fukunaga et al., “Diagnostic criteria of primary osteoporosis,” Journal of Bone and Mineral Metabolism, vol. 16, no. 3, pp. 139–150, 1998.
[3] E. S. Muto, R. Adler, J. Bilezikian et al., “The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance working group,” Osteoporosis International, vol. 25, no. 5, pp. 1439–1443, 2014.
[4] F. Bolognese and W. Xia, “The epidemiology of osteoporosis, associated fragility fractures, and management gap in China,” Arch Osteoporos, vol. 14, no. 1, p. 32, 2019.
[5] A. Oden, E. V. McCloskey, J. A. Kanis, N. C. Harvey, and H. Johansson, “Burden of high fracture probability worldwide: secular increases 2010–2040,” Osteoporosis International, vol. 26, no. 9, pp. 2243–2248, 2015.
[6] L.-Q. Yuan, X. Lin, D. Xiong et al., “Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives,” Clinical Interventions in Aging, vol. 10, pp. 1017–1033, 2015.
[7] Y. Wang, Y. Tao, M. E. Hyman, J. Li, and Y. Chen, “Osteoporosis in China,” Osteoporosis International, vol. 20, no. 10, pp. 1651–1662, 2009.
[8] T. Chandran and I. Venkatachalum, “Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review,” Singapore Medical Journal, vol. 60, no. 7, pp. 364–378, 2019.
[9] S. D. Berry, S. Shi, and D. P. Kiel, “Considering the risks and benefits of osteoporosis treatment in older adults,” JAMA Internal Medicine, vol. 179, no. 8, pp. 1103-1104, 2019.
[10] D. M. Black and C. J. Rosen, “Postmenopausal osteoporosis,” New England Journal of Medicine, vol. 374, no. 3, pp. 254–262, 2016.
[11] M. K. Skjødt, M. Frost, and B. Abrahamsen, “Side effects of drugs for osteoporosis and metastatic bone disease,” British Journal of Clinical Pharmacology, vol. 85, no. 6, pp. 1063–1071, 2019.
[12] Q. Zeng, N. Li, Q. Wang et al., “The prevalence of osteoporosis in china, a nationwide, multicenter DXA survey,” Journal of Bone and Mineral Research, vol. 34, no. 10, pp. 1789–1797, 2019.
[13] P.-C. Leung and W.-S. Siu, “Herbal treatment for osteoporosis: a current review,” Journal of Traditional and Complementary Medicine, vol. 3, no. 2, pp. 82–87, 2013.
[14] Y.-M. Xie, Y. Yuwen, F.-H. Dong et al., “Clinical practice guideline of traditional medicine for primary osteoporosis,” Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 52–63, 2011.
[15] J.-B. Sun, M.-H. Chen, and D.-K. Lin, “New insights into the tonifying kidney-yin herbs and formulas for the treatment of osteoporosis,” Archives of Osteoporosis, vol. 12, no. 1, p. 14, 2017.
[16] B. Shu, Q. Shi, and Y.-J. Wang, “Shen (kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome,” Chinese Journal of Integrative Medicine, vol. 21, no. 9, pp. 656–661, 2015.
[17] H. Lin, X. Wang, Y. Mo et al., “Acupuncture for primary osteoporosis: evidence, potential treatment prescriptions, and mechanisms,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 2705263, 15 pages, 2019.
[18] D. Atkins, D. Best, P. A. Briss et al., “Grading quality of evidence and strength of recommendations,” BMJ (Clinical Research Ed), vol. 328, no. 7454, p. 1490, 2004.
[19] Y. X. Zheng, X. Z. Wang, and Z. K. Zhang, “Bushen Yijing Fang reduces fall risk in late postmenopausal women with osteopenia: a randomized double-blind and placebo-controlled trial,” Scientific Reports, vol. 9, p. 2089, 2019.
[20] H. M. Zhu, L. Qin, P. Garnero et al., “The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis,” Osteoporosis International, vol. 23, no. 4, pp. 1317–1327, 2012.
[21] Z. Q. Zhao and X. X. Yan, “A study on the improvement of clinical symptoms of primary osteoporosis with tonifying kidney method by traditional Chinese medicine,” Chinese Journal of Osteoporosis, vol. 24, no. 3, pp. 371–375, 2018.
[22] Y. Yuan, T. Tang, S. Q. Shi, and W. D. Wang, “Clinical application effect of therapy combined traditional Chinese and western medicine for senile osteoporosis,” Chinese Archives of Traditional Chinese Medicine, vol. 32, no. 8, pp. 2014–2017, 2014.
[23] P. Huang, “Observation on the curative effect of Chinese and Western medicine in the treatment of primary osteoporosis,” Journal of Practical Traditional Chinese Medicine, vol. 31, no. 4. Article ID 2015530819, 298–299 pages, 2015.
[24] W. Wu, D. F. Li, X. Zhi, and H. Meiqing, “Preventive and therapeutic effects of xianling gubao capsules for postmenopausal osteoporosis,” Journal of Guangzhou University of Traditional Chinese Medicine, vol. 22, no. 3, Article ID 2005276556, 191–193 pages, 2005.
[25] B. X. Liu, L. P. Wang, M. Xu et al., “Postmenopausal osteoporosis of liver and kidney deficiency type treated with acupoint catgut embedding by stages,” Chinese Acupuncture & Moxibustion, vol. 31, no. 4, pp. 315–319, 2011.
[26] B. X. Liu, L. P. Wang, M. Xu et al., “Effect of embedding thread at acupoints on TCM syndrome integral and quality of life scale of the patients with postmenopausal osteoporosis of liver and kidney deficiency type,” Chinese Archives of Traditional Chinese Medicine, vol. 29, no. 3, pp. 550–552, 2011.
[27] Y. J. Qi, “Clinical effect of bushen qianggu decoction on senile osteoporosis,” Modern Journal of Integrated Traditional
Evidence-Based Complementary and Alternative Medicine

Chinese and Western Medicine, vol. 25, no. 22, Article ID 2016515893, 2461–2463 pages, 2016.

[28] Y. D. Li, Z. Q. Fan, and C. Y. Lu, "The effect of Bushen Jianpi Decoction assisted with western medicine on senile osteoporosis and its effect on bone mineral density," Nei Mongol Journal of Traditional Chinese Medicine, vol. 36, no. 21, pp. 105-106, 2017.

[29] J. Hu and C. Li, "Observation on the therapeutic effect of Tonifying the kidney and strengthening the spleen on primary osteoporosis," Hubei Journal of Traditional Chinese Medicine, vol. 34, no. 4, Article ID 2012349754, 11–12 pages, 2012.

[30] W. X. Liu and Y. Y. Gong, "Study on the therapeutic effect of Bushen Jianpi Huoxue decoction combined with alendronate sodium tablets on osteoporosis," Shaanxi Journal of Traditional Chinese Medicine, vol. 39, no. 10, pp. 1426–1428, 2018.

[31] S. Chen, L. Xie, Y. Tao, G. Xu, and Y. M. Ma, "Observation on the therapeutic effect of Bushen Jiangu formula combined with salmon calcitonin on senile osteoporosis," Chinese Journal of Traditional Medical Science and Technology, vol. 24, no. 3, pp. 320–321, 2017.

[32] Z. Zou, "Clinical effect of bushen jianhu decoction on postmenopausal osteoporosis," Journal of Modern Medicine & Health, vol. 32, no. 11, pp. 1725–1726, 2016.

[33] J. Han, "Primary osteoporosis randomized parallel group study bushenhuangtang combined western medicine," Journal of Practical Traditional Chinese Internal Medicine, vol. 12, pp. 32–34, 2013.

[34] Y. Q. Huang, M. Shao, S. J. Xu, and T. Jiang, "Clinical observation on bushen tang combined with alendronate sodium tablets for primary osteoporosis with kidney deficiency type," New Chinese Medicine, vol. 50, no. 9, pp. 102–105, 2018.

[35] S. Huang, J. Y. Chen, and H. Gao, "The effect of bushen huoxue recipe on bone density and the biochemical index of bone metabolism in senile osteoporosis," Journal of Clinical Orthopaedics, vol. 20, no. 5, pp. 629–632, 2017.

[36] S. Song, C. Liu, and D. L. Jiang, "Random parallel control study of bushen huoxue recipe combine with miacallic on senile osteoporosis," Journal of Practical Traditional Chinese Internal Medicine, vol. 29, no. 5, pp. 88–90, 2015.

[37] J. Pan and W. T. Ding, "Study on the clinical effect of Bushen Huoxue decoction combined with oyster carbonate in the treatment of primary osteoporosis of middle-aged and old people in rural areas," Chinese Journal of Clinical Rational Drug Use, vol. 33, pp. 133–134, 2014.

[38] X. W. Wang, "Clinical observation on 100 cases of postmenopausal primary osteoporosis treated with Bushen Huoxue Decoction and calcium Erqi," Chinese Journal of Ethnomedicine and Ethnopharmacy, vol. 27, no. 24, pp. 127–129, 2018.

[39] X. Gui, G. X. Gong, and F. M. Huang, "Clinical observation of 60 cases of primary osteoporosis treated with bushen yiqi huayu decocotion," Drugs and Clinic, vol. 14, no. 17, Article ID 2017703424, 18–20 pages, 2017.

[40] B. X. Liu, C. J. Huang, D. B. Liang, and H. W. Tang, "Clinical control study on postmenopausal osteoporosis treated with embedding thread according to syndrome differentiation and medication," Chinese Journal of Integrated Traditional and Western Medicine, vol. 31, no. 10, pp. 1349–1354, 2011.

[41] X. Y. Xie, W. J. Zhang, W. W. Yu, and X. H. Yang, "Effect of gushen recipe on bone turnover in osteoporosis patients," Journal of Guangzhou University of Traditional Chinese Medicine, vol. 35, no. 5, pp. 805–809, 2018.

[42] Y. Liu and C. W. Wang, "Clinical effect of Erxian Bushen decoction combined with warm acupuncture in treating postmenopause osteoporosis with syndrome of kidney-Yang deficiency," Chinese Journal of Experimental Traditional Medical Formulae, vol. 29, no. 9, pp. 162–166, 2016.

[43] D.-M. Xu, H. Xu, J. Liu et al., "of thunder-fire moxibustion on pain, quality of life, and tension of multifidus in patients with primary osteoporosis: a randomized controlled trial," Medical Science Monitor, vol. 24, pp. 2937–2945, 2018.

[44] X. L. Han, Z. J. Lou, and H. W. Lin, "Treatment of senile osteoporosis with shugan wenshen tanyu shuangjie decoction and acupuncture," Gansu Journal of Traditional Chinese Medicine, vol. 24, no. 2, pp. 32–34, 2011.

[45] D. N. Ma and Y. J. Fan, "Study on the effect of combination of traditional Chinese medicine and acupuncture in the treatment of osteoporosis," Contemporary Medical Symposium, vol. 16, no. 7, pp. 58-59, 2018.

[46] G. O. Ouyang, D.-Y. Wang, and X.-M. Xu, "Clinical observation on acupuncture for male osteoporosis," World Journal of Acupuncture-Moxibustion, vol. 31, no. 1, pp. 23–25, 2011.

[47] S. J. Lu, "Effective observation on treating postmenopausal osteoporosis by catgut embedding therapy combined with medicine," Chinese Journal of Traditional Chinese Medicine, vol. 6, no. 11, pp. 48-49, 2014.

[48] N. J. Peng, P. C. Zhong, and X. H. Zhao, "Clinical observation on 35 cases of primary osteoporosis treated by Acupoint Catgut Embedding," Hunan Journal of Traditional Chinese Medicine, vol. 33, no. 10, pp. 101-102, 2017.

[49] N. J. Peng, P. C. Zhong, and X. H. Zhao, "Clinical study of acupoint catgut-embedding on primary osteoporosis," Guiding Journal of Traditional Chinese Medicine and Pharmacy, vol. 24, no. 12, pp. 72–74, 2018.

[50] P. C. Zhong, N. J. Peng, and X. H. Zhao, "Observation of the curative effect of acupoint catgut embedding combined with western medicine on osteoporosis," Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 27, no. 16, pp. 1714–1716, 2018.

[51] Z. W. Lin, "The effect of Shenshu acupoint catgut embedding on bone mineral density of primary osteoporosis," Chinese Journal of Osteoporosis, vol. 12, no. 4, pp. 381-383, 2006.

[52] Z. W. Lin, "Clinical study on Shenshu acupoint catgut embedding therapy for postmenopausal osteoporosis," Journal of Clinical Acupuncture and Moxibustion, vol. 22, no. 4, pp. 1–3, 2006.

[53] X. J. Zou, Y. Y. Hao, J. Hou, and S. L. Pan, "Curative effect observation on point injection of saline combined with routine western medicine for primary senile osteoporosis," Journal of New Chinese Medicine, vol. 50, no. 11, pp. 183–185, 2018.

[54] H. Zhou, N. Q. Wang, C. E. Ting, X. G. Zhou, and J. W. Zhou, "Postmenopausal osteoporosis treated with acupoint injection of salmon calcitonin:a randomized contro," Chinese Acupuncture & Moxibustion, vol. 36, no. 7, pp. 705–708, 2016.

[55] X. Y. Zheng, Clinical Research Guidance of New Chinese Herbal Medicine (China), China Medical Science and Technology Press, 356–360 pages Beijing, China, 2002.

[56] S.-B. Su, W. Jia, A. Lu, and S. Li, "Evidence-based ZHENG: a traditional Chinese medicine syndrome.,” Evidence-based Complementary and Alternative Medicine: ECAM, vol. 2014, Article ID 484201, 2 pages, 2014.

[57] Z. Gao, Y. Lu, U. Halmurat-Upur, J. Jing, and D. Xu, "Study of osteoporosis treatment principles used historically by ancient
physicians in Chinese medicine,” *Chinese Journal of Integrative Medicine*, vol. 19, no. 11, pp. 862–868, 2013.

[58] Y. Liu, J. P. Liu, and Y. Xia, “Chinese herbal medicines for treating osteoporosis,” *Cochrane Database of Systematic Reviews*, vol. 3, Article ID CD005467, 2014.

[59] W.-M. Deng, P. Zhang, H. Huang et al., “Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures,” *Journal of Bone and Mineral Metabolism*, vol. 30, no. 5, pp. 517–524, 2012.

[60] Y. Shen, X. Liu, H. Li, H. Liu, Z. Pan, and G. Chen, “Brain neural effects of the 'tonifying kidney and benefiting marrow' method in the treatment of osteoporosis,” *Journal of Traditional Chinese Medicine*, vol. 39, no. 6, pp. 902–909, 2019.

[61] Q. Bian, J. H. Huang, S. F. Liu et al., “Different molecular targets of Icariin on hMSCs in CORT and OVX -rats,” *Frontiers in Bioscience (Elite Edition)*, vol. 4, pp. 1224–1236, 2012.

[62] H. Wang, M.-H. Ma, S.-S. Nian, and L.-L. Xu, “Anti-osteoporotic activity of icariin in ovariectomized rats,” *Phytotherapy*, vol. 16, no. 4, pp. 320–326, 2009.

[63] J.-F. Li, Y. Zhao, M.-M. Cai, X.-F. Li, and J.-X. Li, “Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity,” *European Journal of Medicinal Chemistry*, vol. 44, no. 7, pp. 2796–2806, 2009.

[64] Z. Yang, J. H. Huang, and S. F. Liu, "The osteoprotective effect of psoralen in ovariectomy-induced osteoporotic rats via stimulating the osteoblastic differentiation from bone mesenchymal stem cells," *Menopause*, vol. 19, no. 10, pp. 1156–1164, 2012.

[65] Y. Zhao, Y. Huai, J. Jin, M. Geng, and J.-X. Li, "Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone resorption and prevents ovariectomy-induced bone loss," *Menopause*, vol. 18, no. 6, pp. 690–697, 2011.

[66] X. Zheng, G. Wu, Y. Nie, and Y. Lin, "Electroacupuncture at the governor vessel and bladder meridian acupoints improves postmenopausal osteoporosis through osteoprotegerin/RANKL/RANK and Wnt/β-catenin signaling pathways," *Experimental and Therapeutic Medicine*, vol. 10, no. 2, pp. 541–548, 2015.

[67] G.-Z. Chen, Y.-X. Xu, J.-W. Zhang, S.-H. Liu, and Z.-Y. Guo, "Effect of acupoint catgut-embedding on the quality of life, reproductive endocrine and bone metabolism of postmenopausal women," *Chinese Journal of Integrative Medicine*, vol. 16, no. 6, pp. 498–503, 2010.

[68] L. Zhang, Y. Wang, Y. Xu et al., "Metabonomic analysis reveals efficient ameliorating effects of acupoint stimulations on the menopause-caused alterations in mammalian metabolism," *Scientific Reports*, vol. 4, p. 3641, 2014.